1-(噻唑-2-基)乙醇 | 40982-30-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(噻唑-2-基)乙醇
• 中文别名: 1-噻唑-2-乙醇
• 英文名称: 1-(2-Thiazolyl)ethanol
• 英文别名: 1-(thiazol-2-yl)ethanol；1-(thiazol-2-yl)ethan-1-ol；1-Thiazol-2-yl-ethanol；1-(1,3-thiazol-2-yl)ethanol
• CAS: 40982-30-7
• 化学式: C₅H₇NOS
• mdl: MFCD13184171
• 分子量: 129.183
• InChiKey: YTYLXXDUJXUJJJ-UHFFFAOYSA-N

物化性质

• 沸点：
  200℃
• 密度：
  1.251
• 闪点：
  75℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  1-(噻唑-2-基)乙醇 在 nickel(IV) oxide 、 sodium dichromate 、 一水合肼 作用下， 以 二氯甲烷 、 水 、 溶剂黄146 为溶剂， 反应 1.5h， 生成 3-methylthiazolo[3,2-c][1,2,3]triazole
  参考文献：
  名称：

  1,2,3-triazolo[5,1-b]thiazoles; synthesis and properties

  摘要：

  The synthesis of 1,2,3-triazolo[5,1-b]thiazole (15) and its 3-methyl- (16) and 3-phenyl- (17) derivatives is reported, together with their spectra, quaternisation, and ring opening reactions.

  DOI：

  10.1016/s0040-4020(01)87090-3
• 作为产物：
  描述：

  3-methylthiazolo[3,2-c][1,2,3]triazole 在 正丁基锂 、 硫酸 作用下， 反应 12.17h， 生成 1-(噻唑-2-基)乙醇
  参考文献：
  名称：

  1,2,3-Triazolo[5,1-b]thiazoles. Part 2 Lithiation experiments leading to 2,4-disubstituted thiazoles

  摘要：

  3-Methyltriazolothiazole (2) and 3-phenyltriazolothiazole (3) were regiospecifically lithiated at position 6, triazolothiazole (1) at position 6 and 3 with the former predominating. The lithiated triazolothiazoles (4), (10) and (11) reacted with a number of electrophiles to give x:6-disubstituted triazolothiazoles, which could be converted into 2,4-disubstituted thiazoles.

  DOI：

  10.1016/s0040-4020(01)87091-5

文献信息

• Purification and Characterization of an NADH-Dependent Alcohol Dehydrogenase from<i>Candida maris</i>for the Synthesis of Optically Active 1-(Pyridyl)ethanol Derivatives
  作者：Shigeru KAWANO、Miho YANO、Junzo HASEGAWA、Yoshihiko YASOHARA

  DOI：10.1271/bbb.100528

  日期：2011.6.23

  A novel (R)-specific alcohol dehydrogenase (AFPDH) produced by Candida maris IFO10003 was purified to homogeneity by ammonium sulfate fractionation, DEAE-Toyopearl, and Phenyl-Toyopearl, and characterized. The relative molecular mass of the native enzyme was found to be 59,900 by gel filtration, and that of the subunit was estimated to be 28,900 on SDS-polyacrylamide gel electrophoresis. These results suggest that the enzyme is a homodimer. It required NADH as a cofactor and reduced various kinds of carbonyl compounds, including ketones and aldehydes. AFPDH reduced acetylpyridine derivatives, β-keto esters, and some ketone compounds with high enantioselectivity. This is the first report of an NADH-dependent, highly enantioselective (R)-specific alcohol dehydrogenase isolated from a yeast. AFPDH is a very useful enzyme for the preparation of various kinds of chiral alcohols.

  一种由Candida maris IFO10003产生的新型（R）-特异性醇脱氢酶（AFPDH）通过硫酸铵分级、DEAE-Toyopearl和Phenyl-Toyopearl纯化至均一，并进行了表征。通过凝胶过滤法测得该酶的原分子质量为59,900，而在SDS-聚丙烯酰胺凝胶电泳中亚基的估计分子质量为28,900。这些结果表明该酶为同源二聚体。它需要NADH作为辅因子，并能还原包括酮和醛在内的多种羰基化合物。AFPDH能高对映选择性地还原乙酰吡啶衍生物、β-酮酯和某些酮化合物。这是首例从酵母中分离出的依赖NADH的高对映选择性（R）-特异性醇脱氢酶的报道。AFPDH对于制备多种手性醇是非常有用的酶。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ NLRP
  申请人：IFM TRE INC

  公开号：WO2019023145A1

  公开（公告）日：2019-01-31

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一个方面，特色化合物AA的公式，或其药学上可接受的盐。在公式AA中显示的变量如索引中所定义。公式AA的化合物是NLRP3活性调节剂，因此可用于治疗代谢性疾病（例如2型糖尿病、动脉粥样硬化、肥胖或痛风）、中枢神经系统疾病（例如阿尔茨海默病、多发性硬化症、肌萎缩性侧索硬化或帕金森病）、肺部疾病（例如哮喘、慢性阻塞性肺疾病或肺部特发性纤维化）、肝脏疾病（例如NASH综合征、病毒性肝炎或肝硬化）、胰腺疾病（例如急性胰腺炎或慢性胰腺炎）、肾脏疾病（例如急性肾损伤或慢性肾损伤）、肠道疾病（例如克罗恩病或溃疡性结肠炎）、皮肤疾病（例如牛皮癣）、肌肉骨骼疾病（例如硬皮病）、血管障碍（例如巨细胞动脉炎）、骨骼疾病（例如骨关节炎、骨质疏松症或骨质增生疾病）、眼部疾病（例如青光眼或黄斑变性）、病毒感染引起的疾病（例如HIV或艾滋病）、自身免疫疾病（例如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE NLRP
  申请人：IFM TRE INC

  公开号：WO2019023147A1

  公开（公告）日：2019-01-31

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一方面，特征在于公式AA的化合物，或其药用可接受的盐。公式AA中所示的变量如权利要求中所定义。公式AA的化合物是NLRP3活性的调节剂，因此，可用于治疗代谢紊乱（例如2型糖尿病、动脉硬化、肥胖或痛风）、中枢神经系统疾病（例如阿尔茨海默病、多发性硬化症、肌萎缩侧索硬化症或帕金森病）、肺病（例如哮喘、慢性阻塞性肺病或特发性肺纤维化）、肝病（例如非酒精性脂肪肝炎、病毒性肝炎或肝硬化）、胰腺病（例如急性胰腺炎或慢性胰腺炎）、肾病（例如急性肾损伤或慢性肾损伤）、肠病（例如克罗恩病或溃疡性结肠炎）、皮肤病（例如银屑病）、肌肉骨骼疾病（例如硬皮病）、血管障碍（例如巨细胞动脉炎）、骨骼疾病（例如骨关节炎、骨质疏松症或骨石化病）、眼病（例如青光眼或黄斑变性）、由病毒感染引起的疾病（例如HIV或艾滋病）、自身免疫病（例如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。
• Kinetic Resolution of Racemic 1-Heteroarylalkanols by Asymmetric Esterification Using Diphenylacetic Acid with Pivalic Anhydride and a Chiral Acyl-transfer Catalyst
  作者：Isamu Shiina、Keisuke Ono、Kenya Nakata

  DOI：10.1246/cl.2011.147

  日期：2011.2.5

  A variety of optically active 1-heteroarylalkanols and their esters, which include heteroaromatic moieties, such as 2-furyl, 2-thienyl, 3-thienyl, 2-thiazoyl, 2-benzothiazoyl, and 2-benzoxazoyl gro...

  各种光学活性的 1-杂芳基烷醇及其酯，包括杂芳族部分，如 2-呋喃基、2-噻吩基、3-噻吩基、2-噻唑基、2-苯并噻唑基和 2-苯并恶唑基等...
• Method and composition for rejuvinating cells, tissues organs, hair and nails
  申请人：——

  公开号：US20020188015A1

  公开（公告）日：2002-12-12

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一个实施例中，本发明涉及包含药物组合物的化合物和组合物，其中药物组合物包含这些化合物，并且相关方法解耦蛋白质、脂质、核酸和其他生物材料以及它们的任意组合的糖介导偶联。在另一个实施例中，这些组合物和相关方法在体内具有实用性，用于减少生物体暴露于内部摄入、经皮应用或其他方式的化合物或组合物时，糖介导偶联过程的有害影响。在另一个实施例中，这些组合物和相关方法对器官、细胞和组织的离体处理以及头发、指甲和皮肤的外部处理具有用处，通过改变可变性和增加组织扩散系数来使它们恢复活力。在另一个实施例中，本发明涉及新颖的化合物和药物组合物。